Vifor Sued for Damages on Process for Making Injectafer Drug (1)

Biofer SpA filed a lawsuit alleging that Vifor Pharma AG’s process for making the active ingredient in Injectafer, an injectable anemia treatment sold in the U.S. by Daiichi Sankyo Inc.’s American Regent, infringes a Biofer patent.

If Vifor “did not use Biofer’s patented process, it would be unable to produce the Injectafer product having the attributes it has,” Biofer says. Those attributes include high bioavailability and a longer shelf life, according to a complaint filed April 15 in the U.S. District Court for the Eastern District of New York.

Biofer, based in Italy, seeks profits lost to, and ...